White & Case advises Karo Healthcare on £235 million acquisition of Lamisil from Haleon

Press Release
1 min read

Global law firm White & Case LLP has advised Karo Healthcare on the £235 million acquisition of the rights to over-the-counter skin healthcare brand Lamisil from Haleon UK Holdings Ltd.

Owned by EQT since 2019, Karo Healthcare is a European consumer healthcare company with brands such as E45, Pevaryl, Proct and AlphaFood. Its products are available in more than 90 countries.

Lamisil is a global brand for the treatment of fungal skin infections.

Haleon is one of the largest consumer healthcare companies in the world, with brands including Sensodyne toothpaste, Panadol, Advil pain relievers, and Centrum vitamins.

The White & Case team which advised on the transaction was led by partner Patrik Erblad (Stockholm, London) and included partners Michael Weir, Philip Trillmich, Nicholas Greenacre (all London), Oscar Liljeson (Stockholm) and Sara Nordin (Brussels, Stockholm), counsel David Tayler (Stockholm) and associates, Jonas Brandt, Mana Sohrabi, Erik Holm (all Stockholm), James Charteris-Black, Alex Robinson, Vishnu Rege, Sarah Lee, Alexandria Davis (all London), Victor Åberg (Helsinki), Norah Arafeh, Rhona Luithle (both London) and Tigran Saakyan (Dubai).

Press contact
For more information please speak to your local media contact.